Neurobiology of Opioid Dependence: 5 - 5

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000196

Purpose

The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Naltrexone	Phase II

Study Type:	Interventional
Study Design:	Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Neurobiology of Opioid Dependence: 5

Resource links provided by NLM:

Drug Information available for: Naltrexone Naltrexone hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Behavioral, physiological, neuroendocrine response to yohimbine

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000196

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Marc I Rosen, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000196 History of Changes
Other Study ID Numbers:	NIDA-00191-5, K20-00191-5
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Naltrexone
Analgesics, Opioid
Narcotic Antagonists
Physiological Effects of Drugs

Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on February 12, 2012